CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Chardan 7th Annual Genetic Medicines Conference in New York City on Monday, October 2, 2023. Dr. Bolno will participate in the ADAR Editing Panel at 9:30 a.m. ET and an analyst-led fireside chat at 10:30 a.m. ET.
A live webcast of the fireside chat will be available on the Investor Relations page of the Wave Life Sciences website at http://ir.wavelifesciences.com. A replay of the ADAR Editing Panel will be available after the conclusion of the conference. Both replays will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) @WaveLifeSci.
Investor Contact:
Kate Rausch
+1 617-949-4827
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Alicia Suter
+1 617-949-4817
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.24 |
| Daily Change: | 0.29 4.17 |
| Daily Volume: | 1,385,774 |
| Market Cap: | US$1.100B |
May 08, 2025 March 04, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
